emergency intubations determined that succinylcholine is superior to rocuronium in achieving excellent intubating conditions, there was no difference between the 2 drugs in terms of clinically acceptable intubating conditions. In the pediatric subgroup analysis, there was no difference between rocuronium and succinylcholine; however, the sample size was small and substantial heterogeneity was identified. None of the trials in this systematic review reported severe adverse outcomes.
Meta-analytic results for rocuronium versus succinylcholine for rapid sequence intubation. 
STUDY SELECTION
All randomized controlled trials and controlled clinical trials were reviewed that compared the use of rocuronium (0.6 mg/kg) and succinylcholine (1 mg/kg) for rapid sequence intubation and reported intubating conditions. Patients of any age were included in any clinical setting.
DATA EXTRACTION AND SYNTHESIS
Two authors independently screened studies for inclusion, extracted data, and assessed methodological quality, using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Study bias was assessed with the risk-of-bias tool. Patient analysis followed the intention-to-treat principle. Treatment effects were reported with a random-effects model and heterogeneity was assessed with the I 2 statistic.
Commentary
Selecting the ideal paralytic for rapid sequence intubation is often challenging, and there may be specific cases in which one paralytic is preferred over another; however, identifying one agent that overall creates more ideal intubating conditions is important. In this updated systematic review, succinylcholine was determined to be superior to rocuronium for producing excellent intubating conditions overall and also in the subgroup of emergency intubations.
The ongoing debate about succinylcholine and rocuronium must weigh the risks and benefits of each paralytic. The benefits of succinylcholine include a rapid onset (50 seconds) and a short duration of action (7 to 11 minutes). 1 Because succinylcholine is a depolarizing neuromuscular blocker, there is a risk of malignant hyperthermia-and hyperkalemiainduced cardiac arrhythmias in patients with "denervation syndromes" (eg, amyotrophic lateral sclerosis, multiple sclerosis, GuillainBarré) and in patients who began "denervation states" 48 to 72 hours earlier, including spinal cord injuries, major burns, and crush injuries. 2 A recent study found that, compared with rocuronium, succinylcholine was associated with increased mortality in emergency department patients with severe traumatic brain injury who underwent rapid sequence intubation. 3 The benefits of rocuronium include a rapid onset (55 to 90 seconds) and no known contraindications. 1 However, because rocuronium is a nondepolarizing blocker and it has an intermediate duration of action (37 to 73 minutes), it may be less desirable under certain clinical situations.
1 Prolonged paralysis can be problematic for patients with a difficult airway, with unstable vital signs, or requiring frequent neurologic checks.
The dosing of rocuronium is an important covariate because it may have an effect on intubating conditions. In subgroup analysis, although succinylcholine was superior to rocuronium at doses of 0.6 to 0.7 mg/kg, there was no difference at doses of 0.9 to 1.0 mg/kg or 1.2 mg/kg. Although the small sample size of the higher doses prevented drawing a conclusion, Patanwala et al 4 found equivalency between succinylcholine and rocuronium at these higher doses. 
